Tanzania has taken a decisive step to make its pharmaceutical market more attractive to investors by introducing a new Regulatory Reliance Pathway that shortens medicine‑registration timelines and reduces duplicated assessments.
The reform, announced by the Tanzania Medicines and Medical Devices Authority (TMDA) in late June, allows the authority to rely on scientific evaluations already conducted by recognised international regulators when reviewing eligible medicines. For pharmaceutical companies, this means less red tape and faster access to one of East Africa’s growing healthcare markets.
90 Days to Market Entry
Under the new pathway, companies whose products have already been authorised by a qualifying Reference Regulatory Authority (RRA) can apply through the reliance route. TMDA has committed to delivering outcomes within 90 working days once an application is accepted for review.
The authority says the system is designed to accelerate approvals, minimise duplication, and maintain safety and efficacy standards, while giving investors greater predictability in planning market entry.
Why Investors Should Pay Attention
For multinational pharmaceutical firms, the reform addresses a critical barrier: the cost and time of duplicating regulatory assessments in every new market.
By recognising trusted international approvals, Tanzania is signalling that it wants to be part of a regional pharmaceutical value chain. This creates opportunities not only in finished medicines, but also in:
- Generic drug production
- Contract manufacturing
- Distribution and cold‑chain logistics
- Packaging
- Research and development
- Quality‑control laboratories
Part of a Bigger Industrial Push
The reform aligns with Tanzania’s wider ambition to expand domestic pharmaceutical production and reduce reliance on imports. TMDA has been actively promoting the country as a destination for pharmaceutical investment, highlighting opportunities for technology transfer and manufacturing partnerships.
Tanzania is also integrating into continental initiatives such as the African Union Smart Safety Surveillance (AU‑3S) programme, which strengthens regulatory harmonisation and safety monitoring across Africa.
Investor Outlook
For global pharmaceutical companies, the significance of the June 2026 reform goes beyond faster approvals. It signals regulatory predictability, a key factor in investment decisions.
By combining a clearer pathway with ambitions for local manufacturing, Tanzania is positioning itself as a regional hub for pharmaceutical production and distribution.
For investors, the message is clear: Tanzania is not only seeking capital for factories, it is building a regulatory environment that makes market entry faster, safer, and more commercially viable.
